IDRSF News and Press, Idorsia Ltd Registered Shares

2026-02-26 14:17:47 ET Idorsia Ltd (IDRSF) Q4 2025 Earnings Call February 26, 2026 8:00 AM EST Company Participants Srishti Gupta - CEO & Executive Director Arno Groenewoud - Executive VP & CFO Conference Call Participants Raghuram Selvaraju - H...

2026-02-26 11:54:02 ET More on Idorsia Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Seeking Alpha’s Quant Rating on Idorsia ...

2026-01-14 18:35:59 ET Idorsia Ltd (IDRSF) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 1:30 PM EST... Read the full article on Seeking Alpha For further details see: Idorsia Ltd (IDRSF) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

New analysis of a Phase 3 study of daridorexant shows that 50 mg improved both sleep and daytime functioning compared to placebo in women during menopausal transition age Brigham and Women’s Hospital to study the effectiveness and safety of daridorexant for menopause-related insomnia symp...

New analysis from landmark Phase 3 PRECISION trial published in Hypertension highlights the renal-protective benefits of aprocitentan in addition to the marked reduction in blood pressure in a high-risk CKD population with difficult-to-control hypertension Allschwil, Switzerland &#x...

New analysis from landmark Phase 3 PRECISION trial published in the Journal of Hypertension highlights aprocitentan led to improvements in dipping pattern and BP load Findings reinforce the role of aprocitentan’s novel endothelin pathway mechanism in addressing significant medi...

New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic kidney disease Allschwil, Switzerland – November 05, 2025 Idorsia Ltd (SIX: IDIA) shares t...

2025-09-08 12:30:22 ET Idorsia Ltd (IDRSF) TRYVIO Investor Q&A Webcast and Conference Call Company Participants Srishti Gupta - CEO & Executive Director Martine Clozel - Executive VP, Chief Scientific Officer & Head of Research Alessandro Maresta ...

Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-scheduled insomnia therapies Allschwil, Switzerland – September 8, 2025 Idorsia Ltd (SIX: IDIA) presented real-wo...

Allschwil, Switzerland – August 28, 2025 Idorsia Ltd (SIX: IDIA) releases an OnDemand investor webcast outlining how TRYVIO™ (aprocitentan) – the first and only hypertension therapy targeting the endothelin pathway – fits into the treatment landscape for di...